ALTIMMUNE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.11 USD | -7.56% |
|
-5.34% | -45.69% |
Presenter SpeechEliana Merle (Analysts)Hi, everyone. Good morning. I'm Ellie Merle, one of the...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Calendar
08/08/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
6.11
USD
Average target price
20.57
USD
Spread / Average Target
+236.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.69% | 43Cr | |
| +18.15% | 12TCr | |
| +18.02% | 11TCr | |
| +5.07% | 2.29TCr | |
| -12.75% | 2.22TCr | |
| -9.86% | 1.7TCr | |
| -14.97% | 1.69TCr | |
| -39.94% | 1.69TCr | |
| +2.80% | 1.36TCr | |
| +27.39% | 1.16TCr |
- Stock Market
- Equities
- ALT Stock
- News Altimmune, Inc.
- Transcript : Altimmune, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 10
